6505--Allopurinol Tablets Effective May 30, 2026 to May 29, 2027

The contract involves the procurement of Allopurinol Tablets, specifically 100MG and 300MG dosages, for supply to the Department of Veterans Affairs and other federal agencies, under a requirements-based, indefinite delivery contract. The solicitation, issued by the VA’s National Acquisition Center, aims to establish a single responsible contractor for a base period of one year with four additional one-year option periods, allowing flexibility to meet estimated annual usage needs across various package sizes. The procurement emphasizes strict packaging, labeling, and barcoding standards, including unit-level GS1 or HIBC compliant bar codes with human-readable NDCs, ensuring traceability and compliance with healthcare standards. The contract clauses incorporate FAR and VAAR provisions addressing small business utilization, equal opportunity, labor standards, trafficking in persons, and supply chain security, reflecting a comprehensive compliance framework. Offerors are required to submit detailed pricing for all line items covering the base and option years, with proposals due electronically by late November 2025. The evaluation will primarily consider price, with technical acceptability assessed based on past performance, subcontracting plans, and compliance with the specified standards. Delivery performance is expected at designated Prime Vendor distribution centers nationwide, with shipments made after receipt of valid orders. The contract emphasizes strict adherence to inspection and acceptance criteria at the point of delivery, ensuring product quality and regulatory compliance. Overall, this procurement seeks a responsible vendor capable of providing pharmaceutical supplies that meet rigorous federal standards, with a focus on transparency, security, and cost-effectiveness.